On Sep 17st 2024, Cell Reports Medicine (IF=11.7), a premium medicine journal from Cell Press, published online a research paper titled” Dietary vitamin B3 supplementation induces the antitumor immunity against liver cancer via biased GPR109A signaling in myeloid cell”, by the joint team of Prof. Hui Wang and Dr. Xiaoguang Li from School of Public Health of Shanghai Jiao Tong University, which identified the effect and underlying mechanism of Dietary vitamin B3 (VB3) in the prevention and treatment of liver cancer. The discovery reports VB3 supplementation as an adjunctive treatment for liver cancer. VB3 demonstrates antitumorefficacy in multiple mouse models through alleviating GPR109A/NF-kB mediated immunosuppression in tumor infiltrated myeloid cells, thereby augmenting effectiveness ofimmunotherapy or targeted therapy in a CD8+T cell-dependent manner.
The impact of dietary nutrients on tumor immunity remains an area of ongoing investigation, particularly regarding the specific role of vitamins and their mechanism. Here, we demonstrate that VB3 induces anti-tumor immunity against liver cancer through biased GPR109A axis in myeloid cell. Nutritional epidemiology studies suggest that higher VB3 intake reduces liver cancer risk. VB3 supplementation demonstrates antitumor efficacy in multiple mouse models through alleviating immunosuppressive tumor microenvironment (TME) mediated by tumor-infiltrating myeloid cell, thereby augmenting effectiveness of immunotherapy or targeted therapy in CD8+T cell-dependent manner. Mechanically, TME induces aberrant GPR109A/NF-κB activation in myeloid cell to shape immunosuppressive TME. In contrast, VB3 activates β-Arrestin-mediated GPR109A degradation and NF-κB inhibition to suppresses the immunosuppressive polarization of myeloid cell, thereby activating cytotoxic function of CD8+T cell. Overall, these results expand understanding of how vitamins regulate TME, suggesting that dietary VB3 supplementation is an adjunctive treatment for liver cancer.
Dr. Yang Yang, Xiaolin Hu, and MS. Tianduo Pei, Yu Lu are the first authors. Prof. Hui wang and Xiaoguang Li are the co-corresponding author. The research was supported by the National Natural Science Foundation of China, the National Key R&D Program of China, the Science and Technology Commission of Shanghai Municipality, Natural Science Foundation of Shanghai and the Innovative research team of high-level local universities.
Original link:
https://www.cell.com/cell-reports-medicine/fulltext/S2666-3791(24)00439-7